Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Sales | 29,568 | 39,003 | 31,853 | 33,336 | 42,499 |
| Cost of Goods | 7,544 | 8,002 | 9,134 | 8,308 | 7,762 |
| Gross Profit | 22,024 | 31,001 | 22,719 | 25,028 | 34,737 |
| Operating Expenses | 50,094 | 53,578 | 45,596 | 47,059 | 51,668 |
| Operating Income | -27,526 | -22,575 | -22,743 | -21,723 | -16,169 |
| Interest Expense | 5,448 | 5,599 | 5,253 | 5,249 | 3,876 |
| Other Income | 287 | 366 | 334 | 397 | 229 |
| Pre-tax Income | -32,687 | -27,808 | -27,662 | -26,575 | -19,816 |
| Income Tax | 210 | -422 | 1,284 | 300 | 0 |
| Net Income Continuous | -32,897 | -27,386 | -28,946 | -26,875 | -19,816 |
| Net Income | $-32,897 | $-27,386 | $-28,946 | $-26,875 | $-19,816 |
| EPS Basic Total Ops | -0.26 | -0.21 | -0.23 | -0.21 | -0.16 |
| EPS Basic Continuous Ops | -0.26 | -0.21 | -0.23 | -0.21 | -0.16 |
| EPS Diluted Total Ops | -0.26 | -0.21 | -0.23 | -0.21 | -0.16 |
| EPS Diluted Continuous Ops | -0.26 | -0.21 | -0.23 | -0.21 | -0.16 |
| EBITDA(a) | $-26,908 | $-9,252 | $-21,981 | $-20,916 | $-15,467 |